cyrilzakka/clinical-trials huggingface dataset:
Predictors of Antimicrobial Resistance in the Respiratory Intensive Care Unit of Alexandria Main University Hospital

The goal of this clinical trial is to identify the predictors of antibiotic resistance whether clinical or laboratory or radiological or all

The goal of this clinical trial is to identify the predictors of antibiotic resistance like the history of previous antibiotic ,the antibiogram of the centre , comorbidities,..etc to decide the suitable antibiotic

Eligibility Criteria:
Inclusion Criteria:

* Adult patient admitted to the respiratory ICU due to bacterial infection.

  * Recent antibiotic intake in the past three months.
  * Intercostal tube insertion for empyema.
  * Shocked patients with inserted central venous catheter.
  * Intubated or tracheostomized patients.
  * Patients with grade two to four bed sores.

Exclusion Criteria:

* . Inability to provide written informed consent for the study.

  * Non sterile sample collection technique.
  * Inability to provide antibiogram.
  * Isolated patients due to suspected tuberculosis
Immediate Versus Conventional Loading of Early Placed Dental Implant Supporting Single Crowns

This study focuses on examining the efficacy and clinical performance of immediate loading of early placed single implants.

The aim of the randomized controlled trial is to compare between two loading protocols (immediate versus conventional) of early placed implants (Type 2-3A) in terms of clinical, radiographic, and patient-reported outcomes.

Null hypothesis: There will be no significant differences in implant survival/success, stability, radiographic marginal bone level, and patient reported outcomes between immediately or conventionally loaded and early placed implants.

Study design:

This study is designed as a parallel group randomized controlled trial with an allocation ratio of 1:1.

The (PICO) study design: population will be patients from Jordan University Hospital aged 18 years or older, requiring single tooth replacement (molar or premolar) with dental implants, with sufficient bone volume and controlled oral hygiene. The intervention group will receive immediate loading of early placed implants (within 1 week), while the comparator group will receive conventional loading (after more than 8 weeks). The primary outcome is changes in marginal bone levels, and the secondary outcomes include implant primary osseointegration, stability, patient satisfaction, and various complications.

Both groups will receive early placed implants after 8-12 weeks of healing (Type 2-3A placement). The surgical procedure will follow standardized protocols, with no variations between groups other than the loading time.

Blinded assessors will perform radiographic and clinical evaluations at designated follow-up visits: at implant placement, definitive loading, 6 months, and 1 year. Ethical approval is obtained prior to study commencement, and all participants will provide informed consent.

Eligibility Criteria:
Inclusion Criteria:

1. aged 18 years or older
2. requiring single tooth replacement with dental implants in presence of four bone walls (mandible or maxilla)
3. having adequate bone volume
4. controlled oral hygiene
5. having agreed to take part in the study and willing to comply with the study protocol and follow-up visits

Exclusion Criteria:

1. Any systemic condition that might jeopardize implant surgery
2. history of radiation therapy to the head and neck region
3. history of bisphosphonate therapy or other medications that may affect bone metabolism
4. smoking more than 10 cigarettes/day
5. history of bruxism or parafunctional habits
6. localized/generalized periodontitis
7. patients in need of bone grafting
8. any known allergy or hypersensitivity to implant materials
Testicular Adrenal Rest Tumor in Congenital Adrenal Hyperplasia Patients Attending Assuit University Children Hospital

assessment of the risk factors contributing for TART development in a male child with congenital adrenal hyperplasia.

Congenital adrenal hyperplasia (CAH) is one of the most frequent endocrine disorders. It is characterized by deficient activity of one of the enzymes necessary for adrenal Cortisol synthesis. Autosomal recessive inheritance of deficient 21-hydroxylase (21 OH) activity accounts for more than 90% of cases. \[1\]

One of the most important and frequently detected complications in males with congenital adrenal hyperplasia (CAH) is the development of testicular adrenal rest tumours (TARTs). . \[2\],\[3\]

Testicular adrenal rest tumor is a benign tumor originating from adrenal cells within the testicles; the adrenal cells migrate at 8 weeks of gestation from the urogenital ridge along with the gonadal cells to the testicle. The exact mechanism underlying tumor growth and development is still not well understood . \[4\],\[5\]

The correct diagnosis of TART is important for differential diagnosis with malignant testis tumors, which need orchiectomy, as opposed to TART, usually treated exclusively with exogenous steroids. \[6\].

Although TARTs are always benign, their location in the rete testis could obstructs the seminiferous tubules and causes gonadal dysfunction and infertility. Therefore, it is important to detect and treat TARTs at an early stage, especially in adolescents or young adults. \[5\],\[7\]

testicular ultrasound should be done in order to evaluate the presence of these lesions, its size, location, and characteristics. \[9\]

TARTs in children have mostly been presented as case reports in the literature, and only a limited number of studies have described the prevalence of TARTs in large populations of children . \[2\],\[8\]

As not all male CAH patients are affected by this complication, attempts have been made to identify the risk factors for the development of TARTs . \[7\]

Eligibility Criteria:
Inclusion Criteria:

* All male patients diagnosed as congenital adrenal hyperplasia based on clinical manifestations and laboratory investigations from age of 4 years to age of 18 years.

Exclusion Criteria:

* Patients with other adrenal insufficiency cause and Congenital adrenal hyperplasia that progressed to true precocious puberty
Chocolate Meal Study

This comparative pilot study is designed to compare the rates of gastric emptying and by inference rates of digestion of challenge meals. Two types of meal will be compared, chocolate mousse style dessert and chocolate bars. The information from this study will then be compared to the elicitation times for both objective and subjective symptoms in the allergic patients who have been challenged in a different study using the same two meals.


Eligibility Criteria:
Inclusion Criteria:

* Male (hormonal status of women would introduce more variation within small group)
* Age 20-50y
* BMI 19-30
* Nominally healthy
* Normally eat lunch
* Willing to eat dark chocolate bars and chocolate dessert.
* Provides informed written consent

Exclusion Criteria:

* Smokers or smoked within the last year (smoking affects satiety/hunger and volunteer's will not be able to smoke during the study day at the hospital)
* Diagnosed with any long term illness requiring active treatment e.g. diabetes, cancer, cardiovascular disease
* Have had surgery on the stomach or intestine or suffered from gastrointestinal disease.
* Regular (more than once in 10 days) use of antacids, laxatives
* Diagnosis with any mouth, dental, throat or digestive problem that may affect normal eating and digestion of food.
* Volunteers taking part in another study (other than a questionnaire based study).
* Blood pressure greater than 160/100 or less than 90/50 or 95/55 if symptomatic.
* Individuals with special dietary requirements (eg vegetarians)
* People with eating disorders (eg. anorexia, bulimia)
* If any of the clinical screening results are indicative of a health problem which would affect the volunteers well-being or which would affect the study data.
* Refusal to give permission to inform GP of participation in study
* Allergic to any of the constituents of the test meal
* Recent unexplained weight gain or loss
* History of back problems or any other condition which limit ability to repeatedly sit up and lie down
* Hiatus Hernia
* MRI scanning specific exclusion criteria

  * Cardiac pacemaker or artificial heart valve
  * Head surgery or any surgery in the last 6 months
  * Aneurysm clips (metal clips from surgery)
  * Implant, pump or any medical device in the body (eg cochlear implant, neurostimulator, intra-venticular shunt)
  * Worked with metals (using lathes or grinders) or sustained injury to eyes involving metal splinters or fillings
  * Have artificial eyes or limbs
  * Have been injured with shrapnel or bullets
  * Suffer from fits, blackouts or epilepsy
  * Claustrophobia sufferer
Migraine Treatment in ED

Randomized pilot feasibility study evaluating the impact of introducing behavioral treatment for migraine in the Emergency Department (ED) and prescribing migraine preventive medications in the ED. The study will examine the effect of these treatments, both individually and in combination, on pain severity and headache-related disability. This study is designed to examine the feasibility of comparing four interventions for ED patients presenting with migraine. Group 1: Starting topiramate; Group 2: Doing a brief behavioral intervention; Group 3: Treating with combination therapy of topiramate and behavioral intervention; and Group 4: Standard of Care.


Eligibility Criteria:
Inclusion Criteria:

* age 18 years to 65 years of age
* primary diagnosis of migraine based on the International Classification of headache disorders 3 beta criteria
* having a migraine 3 or more days/month.

Exclusion Criteria:

* Cognitive Behavioral Therapy (CBT), biofeedback or other relaxation therapy in the past year
* being on medication used for migraine prevention (topiramate, propranolol, valproic acid, amitriptyline/nortriptyline/imipramine/desipramine, botulinum toxin, a SNRI, angiotensin-converting enzyme inhibitors (ACE-I) or ARB)
* cognitive deficit or other physical problem with the potential to interfere with behavioral therapy
* substance or alcohol abuse as determined by self-report or prior documentation in the medical record.
Safety and Effectiveness Study: Role Playing Game for Friends and Family of Service Members

This project is a partnership between Soar Technology, the University of Southern California (USC) Center for Innovation and Research on Veterans and Military Families (CIR) and the USC Creative Media and Behavioral Health Center (CM\&BHC) to conduct a Safety and Effectiveness Study (SES) for an educational role-playing game developed by Soar Technology, Inc. The purpose of the intervention to be delivered by Soar Technology is to educate families and friends with the ultimate goal of empowering them to have a conversation with the veteran/service member about readjustment issues. The study will assess the safety and effectiveness of the provided game using personal interviews, play testing, and surveys. The game playing experience is hypothesized to be safe and effective with respect to having conversations with veterans/service members following deployment.

The intervention is a multi-scenario role playing simulation. Participants view the scenario and answer questions about what has been displayed as typical for post deployment service members. Participants receive immediate feedback with respect to expectations set by simulation developers.

Eligibility Criteria:
Inclusion Criteria:

* must be friend or family member to a military veteran or service member who experienced a deployment no earlier than 2007, or who are currently active and have recently returned from a deployment
* be able to read English
* be reachable via cell phone
* age range 18-86
* daily access to the internet
* have a personal email account for contact
* experience with filling out online surveys, or online shopping, or social media, or playing digital games

Exclusion Criteria:

* no acute psychopathology based on PHQ-9 and VAS scores at baseline and VAS and PHQ-2 at pre-test
* must not be active duty military personnel or a veteran at the time of the study
* service member or self is not currently receiving treatment at VA or other mental health facility
Impact of Multisensory Hand Massage on the Well-being of Cancer Patients

The investigators wish to study the impact of a multisensory hand massage on the immediate well-being of cancer patients.


Eligibility Criteria:
Inclusion Criteria:

* The patient must have given their free and informed consent and signed the consent form
* The patient must be a member or beneficiary of a health insurance plan
* Patient treated in the oncology department of CHU Nimes for any form of cancer with an EValuation Immédiate du Bien-Etre (EVIBE) score of 3 or lower

Exclusion Criteria:

* The subject is participating in another category I interventional study, or is in a period of exclusion determined by a previous study
* The subject refuses to sign the consent
* It is impossible to give the subject informed information
* The patient is under safeguard of justice or state guardianship
* Patient allergic to the massage oil
* Patients with visual or auditory problems
* Patients with an infection resulting in hyperthermia
* Patient with hematoma on the hand
* Patient with dermatological problems or painful areas on the hands
* Patients with an EVIBE score greater than 3
Study for Appropriate Operating Table Height for Endotracheal Intubation Under Direct Laryngoscopy

Laryngeal view of the patient and anesthesiologist's discomfort level during endotracheal intubation in relation to the various heights of operating table has not been investigated. The investigators hypothesis is higher table height will improve the laryngeal exposure.

Eight anesthesiologists will be participated. For each anesthesiologist, 20 patients will be enrolled and they will be randomly allocated into one of 4 groups; T10, T8, T6 or T4. The height of operating table will be adjusted prior to commencement of anesthesia induction to place the patient's forehead at one of four anesthesiologist's dermatome levels (T10, T8, T6 or T4) depending on the group. The best laryngeal views will be graded before and after the anesthesiologist's postural change to improve laryngeal visualization of the patient during intubation. Subjective and objective measurement of anesthesiologists' joint flexion during intubation and discomfort ratings for the mask ventilation or intubation will be recorded.

Eligibility Criteria:
Inclusion Criteria:

* have experiences of more than 100 cases of endotracheal intubation

Exclusion Criteria:

* have acute or chronic musculoskeletal disease or pain
Calcineurin Activity in Renal Recipients

The purpose is to define if calcineurin activity is a better biological parameter than blood concentration for the therapeutic tacrolimus monitoring.

Some authors showed that the determination of calcineurin (enzyme of cyclosporin and tacrolimus action) activity was very interesting in bone narrow and hepatic transplant in order to monitor tacrolimus or cyclosporin. Indeed, Furthermore, target Tac concentrations still fail to provide in certain patients an appropriate immunosuppression reflected by rejection. Because a lack of data in renal transplant, we propose to study this population treated by tacrolimus, mycophenolate mofetil and corticoids in the first three months following the transplantation.

Our major aim is to study the relationship between calcineurin activity and immunologic events in 200 renal recipients treated with tacrolimus in the first three months following transplant. Immunologic events could be acute rejections and infraclinical rejections. The second aims are 1) if this relationship exists, to define the threshold predicting acute rejection using ROC-curve, 2) to define variations between pharmacodynamic (calcineurin activity) and pharmacokinetic (whole blood concentrations) tacrolimus monitoring and 3) to compare calcineurin activity in patients with acute rejection and those with borderline rejection. Blood samples will be collected into EDTA-containing vacutainers prior to the tacrolimus morning administration and at 2, 4, 6 and 9 hours following the administration at D7, D14 and D21. Whole blood tacrolimus concentrations and calcineurin activity were measured using LCMSMS and HPLC techniques. After D21, only residual measurements will be carried out at D28, M2 and M3. A comparative statistical analysis will be performed between data defined with and without rejection. In case of difference, a ROC curve analysis could define normal ranges of calcineurin activity.

This is the second study of the Sud FRANCILIEN Institute for Research in Nephrology-Transplantation defined with Nephrology departments in Mondor and BICETRE hospitals and the object "Interest of pharmacodynamics of immunosuppressive drugs in renal-transplant recipients" is a new theme of these teams.

Eligibility Criteria:
Inclusion Criteria:

* adult renal transplant recipients
* treated by tacrolimus (Prograf or ADVAGRAF), corticoids, Cellcept,

Exclusion Criteria:

* patients with a high risk of bad compliance (toxicomania, severe psychiatric troubles)
* multiorgan transplant patients with mTOR inhibitors treatments
* HIV infected patients
* lack of consent for this study
Visual Management for the Radiotherapy Process

The Visual Management for Radiotherapy Practice (VMRTP) aims to analyze, predict, visualize and shorten the waiting times for radiotherapy patients. The hypothesis is that this can be done by the introduction of models that can predict a patient being at risk for waiting too long as well as visual management tools that visualize the radiotherapy process.

In a retrospective cohort of radiotherapy patients, time stamps of various steps in the radiotherapy process (diagnosis, multi-disciplinary board, referral, intake, simulation, treatment planning, quality control, first fraction of radiotherapy) will be collected. These will be combined with patient, tumor and patient-process (e.g. referring physician, treating physician, busy-at-the-time, referring hospital) related features. Based on these a predictive model will be learned that can estimate the probability at various stages of the process that the patient waits too long. Visual management will be developed that can visualize the predicted waiting time.

Process interventions aimed at reducing waiting times will be tested prospectively.

Eligibility Criteria:
Inclusion Criteria:

Patients receiving radiotherapy

Exclusion Criteria:

Patients not receiving radiotherapy
Clinical Value of Molecular Genetic Analyzes in Gynecological Malignomas

The aim of the planned research project is to find out the clinical significance of molecular genetic analyzes in gynecological malignomas. In particular, it will be investigated how the knowledge of a molecular-genetic finding affects the therapeutic decision of the physician. Furthermore, genetic changes in the tumor tissue will be compared with the changes in CTCs, DTCs and cfDNA.


Eligibility Criteria:
Inclusion Criteria:

* Patients with a solid tumor disease
* The presence of a molecular genetic diagnosis of the tumor tissue from practice for human genetics
* Age \> 18 years
* informed consent

Exclusion Criteria:

* life expectancy \<12 months or worse general condition (Karnofsky \<70)
Evaluate Different Extended-release (ER) Tablets/Capsules of AZD1305

To study the properties of different tablets/capsules of AZD1305 in healthy male volunteers.


Eligibility Criteria:
Inclusion Criteria:

* Healthy male between the age of 20 - 45
* Non-smoking

Exclusion Criteria:

* Potassium outside normal reference values
* ECG findings outside normal range
Biospecimen Analysis in Detecting Chemical Concentrations in Patients With Chronic or Infectious Diseases Receiving Meditations

This trial collects and analyzes sweat and saliva samples compared to blood in detecting chemical concentrations in the body in patients with chronic or infectious diseases receiving medications. Wearable sweat sensors are capable of monitoring electrolytes and metabolites (sodium, potassium, glucose, lactate, etc.) for health monitoring and disease diagnosis. Designing wearable sweat sensors capable of providing information regarding drug administration may be challenging due to ultralow concentrations in biofluids. This trial seeks to determine if the use of a smart wristband can accurately measure the levels of chemicals and substances in sweat.

PRIMARY OBJECTIVE:

I. To compare novel, home-based methods of quantitating medication concentrations in either saliva or sweat to the 'gold standard' of liquid chromatography - mass spectrometry of plasma.

SECONDARY OBJECTIVES:

I. To compare novel home-based methods of quantitating substances in either saliva or sweat to the 'gold standard' in plasma.

II. Assess the ease of obtaining home-based samples.

OUTLINE:

Patients undergo collection of sweat samples via Macroduct Sweat Collection System 3710S and saliva and blood samples within 24 hours after medication administrations. Patients also complete questionnaires over 5-10 minutes and have medical charts reviewed.

After completion of study, patients are followed up periodically.

Eligibility Criteria:
Inclusion Criteria:

* Scheduled to receive medications including, but not limited to, cyclophosphamide, mycophenolic acid, mycophenolate mofetil, metformin or busulfan (any dose, any number of doses, any dosing frequency) as part of treatment at any time. Patients with chronic or infectious diseases can participate
* Willingness to:

  * Provide blood, sweat, and saliva samples
  * Permit medical record review

Exclusion Criteria:

* Pilocarpine allergy
* Difficulty with understanding written English
A Post-Marketing Observational Study of VYXEOS™

The purpose of this observational study is to provide data on the incidence and severity of infusion-related reactions during and immediately following each infusion of VYXEOS during the first induction.


Eligibility Criteria:
Inclusion Criteria:

1. The decision to prescribe VYXEOS must have been made prior to enrollment in this study and based upon approved US indications and dosing: 44mg/m2 daunorubicin and cytarabine 100 mg/2 on Days 1, 3, and 5.
2. Ability to understand and voluntarily give informed consent and understand the requirements of the registry.
3. Age ≥ 18 years.
4. Initiating VYXEOS therapy for the first time according to the current prescribing information.
5. Initiating VYXEOS therapy for the first time according to standard institutional practice.

Exclusion Criteria:

1. Prior treatment with VYXEOS.
2. Patients receiving any investigational agent other than VYXEOS (e.g., any drug or biologic agent or medical device that has not received approval in the US) or receiving VYXEOS for any indication not currently approved in the US.